1. The study examined the effects of genetically inhibiting β-site APP cleaving enzyme 1 (BACE1), which produces amyloid beta (Aβ), on functional outcomes after traumatic brain injury (TBI) in young adult mice. 2. The study found that BACE1 knockout mice performed worse on motor and cognitive tests after TBI compared to wild type mice. 3. The results suggest that further study is needed to evaluate therapies targeting BACE1-derived Aβ after TBI, as inhibition may not be beneficial across all age groups and injury severities.